Lymphoma
MAHOGANY
A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Trial overview
Clinical Area
Haemotology
Disease / Condition
Lymphoma
Study Phase
III
Trial Identifiers
GenesisCare Location(s)
Principal Investigator(s)